EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody targeting of mutant calreticulin in myeloproliferative neoplasms

Frederike Kramer iD, Ann Mullally

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.17896 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Frederike Kramer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Calreticulin, Myeloproliferative Disorders, Mutation, Receptors, Thrombopoietin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Congressionally Directed Medical Research Programs, Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in calreticulin are one of the key disease‐initiating mutations in myeloproliferative neoplasms (MPN). In MPN, mutant calreticulin translates with a novel C‐terminus that leads to aberrant binding to the extracellular domain of the thrombopoietin receptor, MPL. This cell surface neoantigen has become an attractive target for immunological intervention. Here, we summarize recent advances in the development of mutant calreticulin targeting antibodies as a novel therapeutic approach in MPN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalreticulinMyeloproliferative DisordersMutationReceptors, ThrombopoietinHumansAnimals

Substanzen

CalreticulinReceptors, ThrombopoietinMPL protein, human

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Broad Institute, Cambridge, Massachusetts, USA.

ORCID-Profile: Frederike Kramer

Förderung

  • NHLBI NIH HHS
  • Congressionally Directed Medical Research Programs
  • Leukemia and Lymphoma Society
  • Starr Cancer Consortium
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Kramer, F., & Mullally, A. (2024). Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17896

Vancouver

Kramer F, Mullally A. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.17896

BibTeX
@article{Kramer2024,
  author = {Kramer, Frederike and Mullally, Ann},
  title = {Antibody targeting of mutant calreticulin in myeloproliferative neoplasms},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.17896}
}
Kostenlos starten →